Clinical Trials
5
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
Phase 1
Completed
- Conditions
- Extracranial Solid NeoplasmAdvanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
- Interventions
- Biological: Anti-OX40 Antibody BMS 986178Drug: TLR9 Agonist SD-101
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 12
- Registration Number
- NCT03831295
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1
Completed
- Conditions
- B-Cell Non-Hodgkin LymphomaSmall Lymphocytic LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisRadiation: Radiation TherapyDrug: TLR9 Agonist SD-101
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 14
- Registration Number
- NCT03410901
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Phase 2
Completed
- Conditions
- Lymphomas: Non-HodgkinLymphoma, Non-HodgkinLymphomaLymphomas: Non-Hodgkin Follicular / Indolent B-Cell
- Interventions
- Radiation: Local radiotherapy
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 30
- Registration Number
- NCT00880581
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Phase 2
Completed
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Biological: CpG-MCL vaccineBiological: PF-3512676Procedure: Vaccine-primed T-cellsProcedure: Autologous hematopoietic stem cell transplant (HSCT)Drug: Standard induction chemotherapy
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 59
- Registration Number
- NCT00490529
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Phase 1
Completed
- Conditions
- Non-Hodgkin LymphomaMycosis Fungoides
- Interventions
- Drug: CPG 7909
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 30
- Registration Number
- NCT00185965
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
News
No news found